MX354772B - Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido. - Google Patents
Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido.Info
- Publication number
- MX354772B MX354772B MX2014001966A MX2014001966A MX354772B MX 354772 B MX354772 B MX 354772B MX 2014001966 A MX2014001966 A MX 2014001966A MX 2014001966 A MX2014001966 A MX 2014001966A MX 354772 B MX354772 B MX 354772B
- Authority
- MX
- Mexico
- Prior art keywords
- faah
- methods
- present
- meta
- peripherally restricted
- Prior art date
Links
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 2
- 235000010290 biphenyl Nutrition 0.000 title 1
- 239000004305 biphenyl Substances 0.000 title 1
- 239000003940 fatty acid amidase inhibitor Substances 0.000 title 1
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 abstract 6
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 abstract 6
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028116 Mucosal inflammation Diseases 0.000 abstract 1
- 201000010927 Mucositis Diseases 0.000 abstract 1
- 201000009053 Neurodermatitis Diseases 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 abstract 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161525636P | 2011-08-19 | 2011-08-19 | |
| PCT/US2012/051478 WO2013028570A2 (en) | 2011-08-19 | 2012-08-17 | Meta-substituted biphenyl peripherally restricted faah inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014001966A MX2014001966A (es) | 2015-04-08 |
| MX354772B true MX354772B (es) | 2018-03-21 |
Family
ID=47747054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014001966A MX354772B (es) | 2011-08-19 | 2012-08-17 | Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9745255B2 (OSRAM) |
| EP (1) | EP2744778B1 (OSRAM) |
| JP (1) | JP6092870B2 (OSRAM) |
| KR (1) | KR102079404B1 (OSRAM) |
| CN (1) | CN104203906B (OSRAM) |
| AU (1) | AU2012299060B2 (OSRAM) |
| BR (1) | BR112014003886B1 (OSRAM) |
| CA (1) | CA2844812C (OSRAM) |
| DK (1) | DK2744778T3 (OSRAM) |
| ES (1) | ES2708723T3 (OSRAM) |
| MX (1) | MX354772B (OSRAM) |
| WO (1) | WO2013028570A2 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100485727B1 (ko) * | 2004-06-24 | 2005-04-27 | 주식회사 바이오리더스 | 폴리감마글루탐산-비타민 복합체 및 그 용도 |
| ES2708723T3 (es) | 2011-08-19 | 2019-04-10 | Univ California | Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo |
| WO2014023325A1 (en) * | 2012-08-06 | 2014-02-13 | Fondazione Istituto Italiano Di Tecnologia | Multitarget faah and cox inhibitors and therapeutical uses thereof |
| ES2908240T3 (es) | 2014-04-07 | 2022-04-28 | Univ California | Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos |
| CN108348468A (zh) * | 2015-08-11 | 2018-07-31 | Eyesiu医疗股份有限公司 | 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒 |
| WO2017197240A1 (en) * | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| MY172113A (en) | 2017-07-05 | 2019-11-14 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
| SG10201807034XA (en) | 2017-09-05 | 2019-04-29 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease |
| GB201802326D0 (en) | 2018-02-13 | 2018-03-28 | Ucl Business Plc | Gene therapy |
| US12023332B2 (en) | 2018-03-05 | 2024-07-02 | Wylder Nation Foundation | Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin |
| AU2020206722A1 (en) * | 2019-01-10 | 2021-07-29 | Travecta Therapeutics Pte. Ltd. | Anandamide compounds |
| US20230313196A1 (en) * | 2020-07-23 | 2023-10-05 | John Mansell | Compositions and methods for treating pain and anxiety disorders |
| CN120965462A (zh) * | 2025-10-17 | 2025-11-18 | 四川奥邦古得药业有限公司 | 用于生产3,5-二醚戊苯的方法及其在制备3,5-二羟基戊苯中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4325889A (en) | 1978-08-04 | 1982-04-20 | Bayer Aktiengesellschaft | Process for the preparation of 1-amino-8-naphthol-3,6-disulphonic acid (H-acid) |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| US5559410A (en) | 1992-12-17 | 1996-09-24 | Valeo Systemes D'essuyage | Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield |
| US5576220A (en) | 1993-02-19 | 1996-11-19 | Arris Pharmaceutical Corporation | Thin film HPMP matrix systems and methods for constructing and displaying ligands |
| US6271015B1 (en) | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
| CA2206192A1 (en) | 1996-06-13 | 1997-12-13 | F. Hoffmann-La Roche Ag | Modulation of lc132 (opioid-like) receptor function |
| AU731672B2 (en) | 1996-12-02 | 2001-04-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating bipolar disorders |
| GB9701453D0 (en) | 1997-01-24 | 1997-03-12 | Leo Pharm Prod Ltd | Aminobenzophenones |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| NZ506465A (en) | 1998-02-26 | 2003-08-29 | Akzo Nobel Nv | Derivatives of azetidine and pyrrolidine |
| CA2330681C (en) | 1998-05-29 | 2008-08-26 | Andrea Giuffrida | Control of pain with endogenous cannabinoids |
| US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
| US20030134894A1 (en) | 1999-04-07 | 2003-07-17 | Daniele Piomelli | Methods of treating mental diseases, inflammation and pain |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| AU2003237882B2 (en) | 2002-05-16 | 2010-04-08 | Sunovion Pharmaceuticals Inc. | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| FR2842808B1 (fr) | 2002-07-25 | 2004-09-10 | Sod Conseils Rech Applic | Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques |
| AU2003279877B2 (en) * | 2002-10-07 | 2010-05-20 | The Regents Of The University Of California | Modulation of anxiety through blockade of anandamide hydrolysis |
| FR2850377B1 (fr) | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866888B1 (fr) | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
| US20070155707A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
| US9316633B2 (en) | 2006-11-16 | 2016-04-19 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
| US20080119549A1 (en) * | 2006-11-20 | 2008-05-22 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| TW200948805A (en) | 2008-03-07 | 2009-12-01 | Sigma Tau Ind Farmaceuti | Enol carbamate derivatives as modulators of fatty acid amide hydrolase |
| PT2488486T (pt) | 2009-10-13 | 2019-11-05 | Ligand Pharm Inc | Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos |
| WO2012015704A2 (en) * | 2010-07-28 | 2012-02-02 | The Regents Of The University Of California | Peripherally restricted faah inhibitors |
| WO2012167133A2 (en) | 2011-06-01 | 2012-12-06 | The Regents Of The University Of California | Inhibitors of anandamide transport and their therapeutic uses |
| ES2708723T3 (es) | 2011-08-19 | 2019-04-10 | Univ California | Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo |
| ES2908240T3 (es) | 2014-04-07 | 2022-04-28 | Univ California | Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos |
-
2012
- 2012-08-17 ES ES12826376T patent/ES2708723T3/es active Active
- 2012-08-17 EP EP12826376.1A patent/EP2744778B1/en active Active
- 2012-08-17 DK DK12826376.1T patent/DK2744778T3/en active
- 2012-08-17 CA CA2844812A patent/CA2844812C/en active Active
- 2012-08-17 BR BR112014003886-4A patent/BR112014003886B1/pt active IP Right Grant
- 2012-08-17 AU AU2012299060A patent/AU2012299060B2/en active Active
- 2012-08-17 WO PCT/US2012/051478 patent/WO2013028570A2/en not_active Ceased
- 2012-08-17 MX MX2014001966A patent/MX354772B/es active IP Right Grant
- 2012-08-17 CN CN201280051448.5A patent/CN104203906B/zh active Active
- 2012-08-17 KR KR1020147007303A patent/KR102079404B1/ko active Active
- 2012-08-17 JP JP2014526261A patent/JP6092870B2/ja active Active
-
2014
- 2014-02-18 US US14/183,073 patent/US9745255B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2744778B1 (en) | 2019-01-16 |
| BR112014003886A8 (pt) | 2018-01-23 |
| HK1198644A1 (en) | 2015-05-22 |
| WO2013028570A3 (en) | 2013-04-18 |
| BR112014003886A2 (pt) | 2017-03-21 |
| AU2012299060B2 (en) | 2017-06-01 |
| CN104203906B (zh) | 2018-03-13 |
| DK2744778T3 (en) | 2019-03-04 |
| EP2744778A2 (en) | 2014-06-25 |
| US9745255B2 (en) | 2017-08-29 |
| WO2013028570A2 (en) | 2013-02-28 |
| CA2844812C (en) | 2019-10-22 |
| ES2708723T3 (es) | 2019-04-10 |
| JP2014527532A (ja) | 2014-10-16 |
| JP6092870B2 (ja) | 2017-03-08 |
| MX2014001966A (es) | 2015-04-08 |
| KR20150100485A (ko) | 2015-09-02 |
| EP2744778A4 (en) | 2015-04-08 |
| KR102079404B1 (ko) | 2020-02-19 |
| NZ622480A (en) | 2016-05-27 |
| CN104203906A (zh) | 2014-12-10 |
| CA2844812A1 (en) | 2013-02-28 |
| AU2012299060A1 (en) | 2014-04-03 |
| US20140288170A1 (en) | 2014-09-25 |
| BR112014003886B1 (pt) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014001966A (es) | Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido. | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| MX367341B (es) | Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades. | |
| MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
| PH12014501963A1 (en) | Inhibitors of beta-secretase | |
| IN2014DN08025A (OSRAM) | ||
| MX366318B (es) | Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1. | |
| MX341110B (es) | Inhibidores de la amida hidrolasa de acidos grasos (faah). | |
| EA201391332A1 (ru) | Лиганды опиоидных рецепторов и способы их применения и получения | |
| WO2012015758A3 (en) | Methods of treating pain | |
| MX2013005392A (es) | Compuestos de hidroxiamida pirimidina como inhibidores de la proteina deacetilasa y metodo de uso de estos. | |
| WO2015011284A3 (en) | Inhibitors of fapp2 and uses thereof | |
| MD20150071A2 (ro) | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni | |
| WO2013119946A8 (en) | Long chain base sphingosine kinase inhibitors | |
| MX348024B (es) | Compuestos de adamantilo. | |
| TN2015000032A1 (en) | Inhibitors of beta-secretase | |
| PH12016501159B1 (en) | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system | |
| WO2011153377A3 (en) | Methods and compositions for treating a subject for central nervous system (cns) injury | |
| WO2012145737A8 (en) | Fatty acid amide hydrolase inhibitors for treating pain | |
| IN2014DN11027A (OSRAM) | ||
| MX2011012140A (es) | Ranolazina para el tratamiento de problemas del snc. | |
| WO2014144836A3 (en) | Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors | |
| WO2012174552A3 (en) | Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system | |
| NZ724799A (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
| GEP20186881B (en) | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |